MEA Underactive Bladder Market - Industry Trends and Forecast to 2029
Middle East and Africa underactive bladder market is projected to register a CAGR of 3.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation
Middle East and Africa Underactive Bladder Market, By Treatment (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of Middle East and Africa underactive bladder market are:
• Rising research and development to develop innovative treatments
• Increasing cases of bladder disorders and training programs
Market Players
The key market players operating in the Middle East and Africa underactive bladder market are listed below:
• Astellas Pharma Inc.
• Aurobindo Pharma.
• Boehringer Ingelheim International GmbH
• Macleods Pharmaceuticals Ltd.
• Orion Corporation
• Novartis AG
• Pfizer Inc.
• Cipla Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Almirall, S.A
• Alkem Labs.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook